- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT05923073
Исследование гуселькумаба у детей с активной болезнью Крона от умеренной до тяжелой степени (MACARONI-23)
Фаза 3, многоцентровое, рандомизированное, платформенное исследование ингибирования p19 пути IL-23 для установления эффективности при детской болезни Крона
The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 3
Контакты и местонахождение
Контакты исследования
- Имя: Study Contact
- Номер телефона: 844-434-4210
- Электронная почта: Participate-In-This-Study1@its.jnj.com
Места учебы
-
-
-
Nedlands, Австралия, 6009
- Рекрутинг
- Perth Children's Hospital
-
South Brisbane, Австралия, 4101
- Рекрутинг
- Mater Hospital Brisbane
-
Westmead, Австралия, 2145
- Рекрутинг
- The Children's Hospital at Westmead
-
-
-
-
-
Vienna, Австрия, 1090
- Рекрутинг
- AKH - Medizinische Universitat Wien
-
-
-
-
-
Brussels, Бельгия, 1090
- Рекрутинг
- Universitair Ziekenhuis Brussel
-
Brussels, Бельгия, 1200
- Рекрутинг
- Cliniques Universitaires Saint Luc
-
Ghent, Бельгия, 9000
- Рекрутинг
- Universitair Ziekenhuis Gent
-
Leuven, Бельгия, 3000
- Рекрутинг
- UZ Leuven
-
-
-
-
-
Campinas, Бразилия, 13060-904
- Рекрутинг
- Sociedade Campineira de Educacao e Instrucao Hospital e Maternidade Celso Pierro
-
Curitiba, Бразилия, 80250-060
- Рекрутинг
- Associacao Hospitalar de Protecao a Infancia Dr. Raul Carneiro
-
Goiânia, Бразилия, 74605-020
- Рекрутинг
- Universidade Federal de Goias - Hospital das Clinicas da UFG
-
Porto Alegre, Бразилия, 90035-074
- Рекрутинг
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Porto Alegre, Бразилия, 90035-007
- Рекрутинг
- Hospital De Clinicas De Porto Alegre
-
Vitória, Бразилия, 29040-091
- Рекрутинг
- Centro de Ciencias e Saude da Universidade Federal do Espirito Santo-Nucleo de Doencas Infecciosas
-
Votuporanga, Бразилия, 100000
- Рекрутинг
- INTEGRAL Pesquisa e Ensino
-
-
-
-
-
Beersheba, Израиль, 84101
- Рекрутинг
- Soroka University Medical Center
-
Be’er Ya‘aqov, Израиль, 70300
- Рекрутинг
- Shamir Medical Center Assaf Harofeh
-
Jerusalem, Израиль, 9103102
- Рекрутинг
- Shaare Zedek Medical Center
-
Jerusalem, Израиль, 9124001
- Рекрутинг
- Hadassah Medical Center
-
Petah Tikva, Израиль, 4920235
- Рекрутинг
- Schneider Children's Medical Center
-
Rehovot, Израиль, 761001
- Рекрутинг
- Kaplan Medical Center
-
-
-
-
-
Córdoba, Испания, 14004
- Рекрутинг
- Hosp Reina Sofia
-
Sabadell, Испания, 8208
- Рекрутинг
- Corporacio Sanitari Parc Tauli
-
Valencia, Испания, 46026
- Рекрутинг
- Hosp. Univ. I Politecni La Fe
-
-
-
-
-
Alessandria, Италия, 15121
- Рекрутинг
- A.O. Santi Antonio e Biagio e Cesare Arrigo
-
Bergamo, Италия, 24127
- Рекрутинг
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
-
Bologna, Италия, 40124
- Рекрутинг
- Ospedale Bellaria, U.O.Cardiologia Az. USL di Bologna
-
Florence, Италия, 50139
- Рекрутинг
- Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
-
Milan, Италия, 20154
- Рекрутинг
- Azienda Socio Sanitaria Territoriale Fatebenefratelli Presidio Ospedale dei Bambini Vittore Buzzi
-
Roma, Италия, 161
- Рекрутинг
- AOU Policlinico Umberto I
-
-
-
-
Nova Scotia
-
Halifax, Nova Scotia, Канада, B3K 6R8
- Рекрутинг
- Iwk Health Centre
-
-
Ontario
-
London, Ontario, Канада, N6A 5W9
- Рекрутинг
- London Health Sciences Centre Victoria Hospital
-
Toronto, Ontario, Канада, M5G 1X8
- Рекрутинг
- Hospital For Sick Children
-
-
-
-
-
Rotterdam, Нидерланды, 3015 GD
- Рекрутинг
- Erasmus Medisch Centrum
-
-
-
-
-
Nordbyhagen, Норвегия, 1474
- Рекрутинг
- Akershus Universitetssykehus HF
-
Oslo, Норвегия, 424
- Рекрутинг
- Oslo University Hospital
-
Tromsø, Норвегия, 9038
- Рекрутинг
- Universitetssykehuset Nord-Norge HF
-
Trondheim, Норвегия, 7030
- Рекрутинг
- St. Olavs Hospital
-
-
-
-
-
Rzeszów, Польша, 35-302
- Рекрутинг
- Korczowski Bartosz Gabinet Lekarski
-
Warsaw, Польша, 04 501
- Рекрутинг
- WIP Warsaw IBD Point Profesor Kierkus
-
Warsaw, Польша, 04 730
- Рекрутинг
- Instytut Pomnik Centrum Zdrowia
-
-
-
-
-
Braga, Португалия, 4710-243
- Рекрутинг
- Hospital de Braga
-
Lisbon, Португалия, 1649-035
- Рекрутинг
- Centro Hospitalar de Lisboa Norte Hospital Santa Maria
-
Porto, Португалия, 4200-319
- Рекрутинг
- Centro Hospitalar de Sao Joao E.P.E.
-
-
-
-
-
Glasgow, Соединенное Королевство, G51 4TF
- Рекрутинг
- Royal Hospital for Sick Children
-
London, Соединенное Королевство, WC1N 3JH
- Рекрутинг
- Great Ormond Street Hospital
-
Manchester, Соединенное Королевство, M13 9WL
- Рекрутинг
- Royal Manchester Children's Hospital
-
Manchester, Соединенное Королевство, M13 9WL
- Рекрутинг
- Nowgen Centre, Research and Innovation
-
Oxford, Соединенное Королевство, OX3 9DU
- Рекрутинг
- John Radcliffe Hospital
-
Sheffield, Соединенное Королевство, S10 2TH
- Рекрутинг
- Sheffield Children's Hospital
-
-
-
-
California
-
Los Angeles, California, Соединенные Штаты, 90048
- Рекрутинг
- Cedars Sinai Medical Center
-
-
Connecticut
-
Hartford, Connecticut, Соединенные Штаты, 06106
- Рекрутинг
- Connecticut Children's Medical Center
-
-
Georgia
-
Atlanta, Georgia, Соединенные Штаты, 30322
- Рекрутинг
- Emory University
-
Atlanta, Georgia, Соединенные Штаты, 30342
- Рекрутинг
- Children's Center for Digestive Health Care
-
-
Indiana
-
Indianapolis, Indiana, Соединенные Штаты, 46202-5225
- Рекрутинг
- Riley Hospital for Children
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02115
- Рекрутинг
- Boston Childrens Hospital
-
-
New Jersey
-
Morristown, New Jersey, Соединенные Штаты, 07960
- Рекрутинг
- Goryeb Children's Hospital
-
-
New York
-
New York, New York, Соединенные Штаты, 10029
- Рекрутинг
- Icahn School of Medicine at Mount Sinai
-
New York, New York, Соединенные Штаты, 10032
- Рекрутинг
- Columbia University Medical Center
-
New York, New York, Соединенные Штаты, 10021-5663
- Рекрутинг
- Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center
-
-
Ohio
-
Dayton, Ohio, Соединенные Штаты, 45404
- Рекрутинг
- The Children's Medical Center of Dayton
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19104
- Рекрутинг
- Children's Hospital of Philadelphia
-
-
Texas
-
Fort Worth, Texas, Соединенные Штаты, 76104
- Рекрутинг
- Cook Childrens Medical Center
-
-
Vermont
-
Colchester, Vermont, Соединенные Штаты, 05446
- Рекрутинг
- University of Vermont Medical Center
-
-
-
-
-
Amiens, Франция, 80054
- Рекрутинг
- CHU Amiens-Hopital Nord
-
Lille, Франция, 59037
- Рекрутинг
- Hôpital Jeanne de FLANDRE, CHRU LILLE
-
Paris, Франция, 75019
- Рекрутинг
- Hôpital Robert Debré
-
Paris, Франция, 75015
- Рекрутинг
- Hôpital Necker - Enfants Malades
-
-
-
-
-
Busan, Южная Корея, 48108
- Рекрутинг
- Inje University Haeundae Paik Hospital
-
Daegu, Южная Корея, 41404
- Рекрутинг
- Kyungpook National University Chilgok Hospital
-
Seoul, Южная Корея, 03080
- Рекрутинг
- Seoul National University Hospital
-
Seoul, Южная Корея, 06351
- Рекрутинг
- Samsung Medical Center
-
Seoul, Южная Корея, 120-752
- Рекрутинг
- Severance Hospital Yonsei University Health System
-
-
-
-
-
Hirosaki, Япония, 036-8563
- Рекрутинг
- Hirosaki University Hospital
-
Kagoshima, Япония, 890-8544
- Рекрутинг
- Kagoshima University Hospital
-
Kashiwa-shi, Япония, 277-0871
- Рекрутинг
- Tsujinaka Hospital Kashiwanoha
-
Kobe, Япония, 650 0017
- Рекрутинг
- Kobe University Hospital
-
Saga, Япония, 849-8501
- Рекрутинг
- Saga University Hospital
-
Sendai, Япония, 989-3126
- Рекрутинг
- Miyagi Childrens Hospital
-
Setagaya Ku, Япония, 157 8535
- Рекрутинг
- National Center for Child Health and Development
-
Tokyo, Япония, 113-8431
- Рекрутинг
- Juntendo University Hospital
-
Tsu, Япония, 514 8507
- Рекрутинг
- Mie University Hospital
-
Ube, Япония, 755-8505
- Рекрутинг
- Yamaguchi University Hospital
-
Yokohama, Япония, 232-0024
- Рекрутинг
- Yokohama City University Medical Center
-
Yokohama, Япония, 230-8765
- Рекрутинг
- Saiseikai Yokohamashi Tobu Hospital
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Participants must have a diagnosis of Crohn's Disease (CD) or fistulizing CD, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic, and histologic criteria.
- Participants must have moderately to severely active CD (as defined by a baseline Pediatric Crohn's Disease Activity Index [PCDAI] score greater than or equal to [>=] 30)
- Participants must have endoscopy with evidence of active CD defined as Simple Endoscopic Score for Crohn's Disease (SES-CD) score greater than or equal to (>=) 6 (or >=4 for participants with isolated ileal disease) within 1 month of receiving study intervention at Week 0
- Participants must have a history of inadequate response, loss of response, or intolerance to immunomodulators (6-MP, AZA, or MTX), oral or IV corticosteroids, or biologic therapy/JAK inhibitor therapy; OR have a history of corticosteroid dependence; OR have a history of inadequate response to exclusive enteral nutrition (EEN)
Exclusion Criteria:
- Participants has complications of CD such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestation that might be anticipated to require surgery.
- Participants must not have an abscess
- Participants must not have any kind of bowel resection within 26 weeks or any other intra-abdominal surgery within 12 weeks of baseline
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Тройной
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Open-label induction phase: Guselkumab Intravenously (IV)
Participants will receive guselkumab dose IV based on their body weight during the 12-week open-label induction phase. |
Guselkumab will be administered subcutaneously.
Другие имена:
Guselkumab will be administered intravenously.
Другие имена:
|
|
Экспериментальный: Open-label induction phase: Guselkumab Subcutaneously (SC)
Participants will receive guselkumab dose SC based on their body weight during the 12-week open-label induction phase. |
Guselkumab will be administered subcutaneously.
Другие имена:
Guselkumab will be administered intravenously.
Другие имена:
|
|
Экспериментальный: Double-blind maintenance phase: Guselkumab SC Dose Regimen 1
At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 1 SC based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
Другие имена:
Guselkumab will be administered intravenously.
Другие имена:
|
|
Экспериментальный: Double-blind Maintenance Phase: Guselkumab SC Dose Regimen 2
At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 2 SC based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
Другие имена:
Guselkumab will be administered intravenously.
Другие имена:
|
|
Экспериментальный: Open-label maintenance phase: Guselkumab SC
Week 12 non-responders will not be randomized and will enter an open-label maintenance phase to receive guselkumab SC dosing regimen based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
Другие имена:
Guselkumab will be administered intravenously.
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Percentage of Participants with Clinical Remission at Week 52
Временное ограничение: Week 52
|
Percentage of participants with clinical remission at Week 52 will be assessed. Clinical remission is defined as pediatric Crohn's Disease activity index (PCDAI) less than or equal to (<=) 10. |
Week 52
|
|
Percentage of Participants Who Achieve Endoscopic Response at Week 52
Временное ограничение: Week 52
|
Percentage of participants who achieve endoscopic response at Week 52 will be assessed. Endoscopic response is defined as greater than or equal to (>=) 50 percent (%) reduction (global) and greater than (>) 50% reduction (U.S specific) from simplified endoscopic score-Crohn's Disease (SES-CD) score at baseline. |
Week 52
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Percentage of Participants with Clinical Response at Week 12
Временное ограничение: Week 12
|
Percentage of participants with clinical response at Week 12 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30. |
Week 12
|
|
Percentage of Participants with Clinical Response at Week 52
Временное ограничение: Week 52
|
Percentage of participants with clinical response at Week 52 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30. |
Week 52
|
|
Percentage of Participants with Clinical Remission at Week 12
Временное ограничение: Week 12
|
Percentage of participants with clinical remission at Week 12 will be assessed. Clinical remission is defined as PCDAI score <=10. |
Week 12
|
|
Percentage of Participants with Endoscopic Remission at Week 52
Временное ограничение: Week 52
|
Percentage of participants with endoscopic remission at Week 52 will be assessed. Endoscopic remission is defined as SES-CD total score <=4 and at least a 2-point reduction from baseline and no subscore >1. |
Week 52
|
|
Percentage of Participants with Corticosteroid-free Remission at Week 52
Временное ограничение: Week 52
|
Percentage of participants with corticosteroid-free remission at Week 52 will be assessed. Corticosteroid-free remission is defined as PCDAI score <=10 at Week 52 and not receiving corticosteroids for at least 90 days before Week 52. |
Week 52
|
|
Percentage of Participants with Sustained Clinical Remission at Weeks 12, 24, and 52
Временное ограничение: Weeks 12, 24, and 52
|
Percentage of participants with sustained clinical remission at Weeks 12, 24, and 52 will be assessed. Sustained clinical remission is defined as PCDAI <=10 at Weeks 12, 24, and 52. |
Weeks 12, 24, and 52
|
|
Percentage of Participants with Clinical remission by Patient-Reported Outcome (PRO-2)
Временное ограничение: Week 12 and/or Week 52
|
Percentage of participants with clinical remission by PRO-2 will be assessed. Clinical remission by PRO-2 is defined as stool frequency (SF) <=3 and abdominal pain (AP) <=1 and no worsening of SF and AP from baseline. |
Week 12 and/or Week 52
|
|
Serum Concentration of Guselkumab During Induction Phase
Временное ограничение: From Week 0 to Week 12
|
Serum concentrations of guselkumab will be assessed. Serum samples will be analyzed to determine concentrations of guselkumab using a validated, specific, and sensitive immunoassay method. |
From Week 0 to Week 12
|
|
Trough Plasma Concentration (Ctrough) of Guselkumab During Maintenance Phase
Временное ограничение: At Weeks 16, 24, 36, 48 and 52
|
Ctrough is defined as the serum concentration of guselkumab immediately prior (pre-dose) to the next drug administration. |
At Weeks 16, 24, 36, 48 and 52
|
|
Change from Baseline in Body Weight at Weeks 12, 24, and 52
Временное ограничение: Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Body Weight Percentiles at Weeks 12, 24, and 52
Временное ограничение: Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight percentiles at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Body Weight z-scores at Weeks 12, 24, and 52
Временное ограничение: Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight z-scores at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height at Weeks 12, 24, and 52
Временное ограничение: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height Percentiles at Weeks 12, 24, and 52
Временное ограничение: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height percentiles at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height z-scores at Weeks 12, 24, and 52
Временное ограничение: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height z-scores at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height Velocity at Weeks 12, 24, and 52
Временное ограничение: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height velocity at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Percentage of Participants with Clinical Remission
Временное ограничение: Week 52
|
Percentage of participants with clinical remission who were assigned to guselkumab dose regimen 1 and did not receive rescue therapy at Week 52 will be assessed. Clinical remission is defined as PCDAI score <=10. |
Week 52
|
|
Percentage of Participants Who Achieve Endoscopic Response
Временное ограничение: Week 52
|
Percentage of participants who achieve endoscopic response who were assigned to q4w maintenance therapy and did not receive rescue therapy at Week 52 will be assessed. Endoscopic response is defined as >=50% reduction (global) and >50% reduction (U.S specific) from SES-CD score at baseline. |
Week 52
|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Временное ограничение: Up to Week 64
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. An SAE is is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important. |
Up to Week 64
|
Соавторы и исследователи
Следователи
- Директор по исследованиям: Clinical Trial, Janssen Research & Development, LLC
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- CR109212
- 2021-006282-37 (Номер EudraCT)
- CNTO1959PBCRD3007 (Другой идентификатор: Janssen Research & Development, LLC)
- 2023-504735-41-00 (Идентификатор реестра: EUCT number)
- 2023 (Грант/контракт NIH США)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .